Patents Assigned to Oreoon Health & Science University
  • Assays and methods for selecting a treatment regimen for a subject with leukemia
    Patent number: 10927418
    Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: February 23, 2021
    Assignees: Celator Pharmaceuticals, Inc., Oreoon Health & Science University
    Inventors: Max Gordon, Paul Tardi, Jeffrey Tyner, Lawrence Mayer